Tag Archive for: AI

Ingenix AI drug development

Warsaw-based AI biology company Ingenix has raised €13m in a seed-extension financing round led by Sofinnova Partners, with participation from Inovo VC and OTB VC.

IMU bioscience fundraising

London-based IMU Biosciences has expanded its Series A financing to more than US$53m (£40m/€46m) in an oversubscribed round, as the company looks to scale its immune-profiling platform and move further into clinical applications.

getty-images-HZfsCshPpiE-unsplash

Perceptic has raised a $12 million (€10.3 million) seed round to advance an AI operating system used by companies including CSL.

control panel AI biotech

Cambridge-based Tolemy Bio has raised €1.4m in pre-seed financing to develop Orbit, an AI-native platform designed to help biopharma teams interpret, optimise and control cell-based therapeutic processes.

Novo Nordisk becomes the latest major pharma player to trust the future of its drug discovery to AI. However, the Danish pharma heavyweight is going one step further: The partnership with Open AI is set to embed advanced artificial intelligence across everything from early R&D to commercial operations.

26-03-11_Panel+discussion+at+the+AI+Circular+Economy+Conference+2026

The AI Circular Economy Conference 2026, organised by nova-Institute, brought together 116 participants from 15 countries in Cologne and online to explore the transformation of the chemical and materials industry supported and accelerated by artificial intelligence.

Ternary co-founders

London-based Ternary Therapeutics has raised a €4.1 million seed round to expand its platform for designing molecular glue drugs, with Paris-based VC daphni leading the financing alongside Pace Ventures, i&i Biotech Fund and Future Planet Capital.

owkin spin out waiv

French AI biotech Owkin has spun out its diagnostics division as a new company, Waiv, raising $33 million in financing led by OTB Ventures and Alpha Intelligence Capital to scale AI-powered precision testing.

As a co-investor in the USD 25 million Series B round, Beiersdorf AG is signalling that artificial intelligence is becoming strategically important for skin research. The Hamburg-based group is participating through its venture unit in the AI biotech Turbine, founded in Budapest and now also headquartered in London.

Oxford-based Brainomix has added £4.8 million (approximately $6.5m/€5.5m) to its Series C financing, bringing the total round to £18.8 million ($25.4m/€21.5m) and providing fresh capital to accelerate the US rollout of its AI-powered imaging platforms for stroke and lung fibrosis.